Condition
Glanzmann's Disease
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01876745Completed
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
NCT01561417Phase 1Completed
Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
NCT00697320Completed
Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
NCT01476423Completed
Observational Registry of the Treatment of Glanzmann's Thrombasthenia
Showing all 4 trials